Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.,Diabetes, Obesity and Metabolism

当前位置： X-MOL 学术 › Diabetes Obes. Metab. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-02-09 , DOI: 10.1111/dom.13995
Mark E Cooper ₁ , Julio Rosenstock _{2,

3} , Takashi Kadowaki _{4,

5} , Yutaka Seino _{6,

7} , Christoph Wanner ₈ , Sven Schnaidt ₉ , Douglas Clark ₁₀ , Odd Erik Johansen ₁₁ ,

Affiliation

Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Dallas Diabetes Research Center at Medical City, Dallas, Texas.
University of Texas, Southwestern Medical Center, Dallas, Texas.
Department of Prevention of Diabetes and Lifestyle-related Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Department of Metabolism and Nutrition, Mizonokuchi Hospital, Faculty of Medicine, Teikyo University, Kanagawa, Japan.
Kansai Electric Power Medical Research Institute, Osaka, Japan.
Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
Division of Nephrology, Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
Boehringer Ingelheim International GmbH, Ingelheim, Germany.
Boehringer Ingelheim Norway KS, Asker, Norway.

In CARMELINA®, linagliptin demonstrated cardiovascular and renal safety in patients with type 2 diabetes (T2D) with high renal and cardiovascular disease (CVD) risk. We investigated safety and efficacy of this dipeptidyl peptidase‐4 inhibitor in older participants.

中文翻译：

接受2型糖尿病和已确定的心血管疾病和/或肾脏疾病的老年人接受利格列汀治疗的心血管和肾脏结局：一项随机，安慰剂对照的CARMELINA®试验的预定亚组分析。

在CARMELINA®中，利格列汀在患有高肾脏和心血管疾病（CVD）风险的2型糖尿病（T2D）患者中显示出心血管和肾脏安全性。我们研究了这种二肽基肽酶-4抑制剂在老年受试者中的安全性和有效性。

更新日期：2020-02-09

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文